Windtree Therapeutics Inc WINT shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target.
Windtree Therapeutics is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. The company's technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant without invasive procedures.
Windtree's development program utilizing its proprietary technology platform is AEROSURF that is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
